DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Millennium Hotel London Mayfair

2017 年 12 月 05 日 8:30 上午 - 2017 年 12 月 06 日 6:30 下午

44 Grosvenor Square Mayfair, London, W1K 2HP, United Kingdom

Clinical Trial Regulation Conference

Session 7: Implementation Status for Clinical Data Publication: Setting the Scene

Session Chair(s)

Robert  Paarlberg, MS

Robert Paarlberg, MS

Principal

Paarlberg & Associates LLC, United States

Matthias  Zerm, PhD

Matthias Zerm, PhD

Lead Expert, Clinical Trial Disclosure and R&D Processes

Germany

The public availability of clinical trial information in on the EU Portal and Database is a key element of the Clinical Trial Regulation (CTReg). While Policy 0070 differs from the CTReg in scope, redacted/anonymised versions of clinical study reports (CSRs) of at least some studies will be published under both rules. Apart from references to Policy 0070, no details are yet available on standards and processes for redacted/anonymised versions of CSRs and other clinical documents to be submitted to the EU Portal under the CTReg framework. This session will focus on the transparency provisions in the CTReg as well as the implementation status of Policy 0070 {backlog, phase II, Technical Anonymisation Group (TAG)} and the status of the Portal used for sharing documents and the technicalities of the process of submitting and accessing documents. The future of the Policy 0070 requirements and process when the CTReg is fully implemented will also be addressed.

Speaker(s)

Matthias  Zerm, PhD

CTReg Transparency Provisions and Their Implementation

Matthias Zerm, PhD

Germany

Lead Expert, Clinical Trial Disclosure and R&D Processes

Anne-Sophie  Henry-Eude, PharmD

EMA Updates on Policy 70

Anne-Sophie Henry-Eude, PharmD

European Medicines Agency, Netherlands

Head of Documents Access and Publication Department

Noemie  Manent, PharmD

How the Portal Works

Noemie Manent, PharmD

European Medicines Agency, Netherlands

TDA-CTT Operations Workstream Lead

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。